Latest Articles

MIT Reprograms Immune Cells Inside the Body to Kill Cancer
Researchers at MIT have developed a method to reprogram patients' own immune cells in vivo, turning them into tumor-seeking cancer killers. The approach promises faster, cheaper, and more accessible immunotherapies but faces safety, delivery, and regulatory hurdles before it can reach widespread clinical use.

2–3 Cups Daily May Cut Dementia Risk — What Science Says
Multiple population studies suggest that drinking two to three cups of coffee daily is associated with a substantially lower risk of dementia; this article explains the evidence, possible biological mechanisms, caveats, and practical guidance for adults considering coffee as part of a brain-healthy lifestyle.

Trump Declares Oval Office a National Monument — What It Means
President Trump signed a proclamation declaring the Oval Office and Cabinet Room national monuments, arguing it preserves their historic character. The move raises immediate legal and political questions about the limits of executive power, how future presidents might respond, and what ‘preservation’ means for a living seat of power.

Physicists Smash Oxygen Nuclei to Recreate Big Bang Matter
Scientists are colliding oxygen nuclei to recreate the extreme, short-lived state of matter that existed microseconds after the Big Bang — the quark-gluon plasma — allowing new tests of how ordinary matter formed. This feature explains the experiment, why oxygen is used, what detectors reveal, and what the results mean for cosmology and particle physics.

Reversing Liver Cell Aging: Study Halves Alzheimer-Linked Protein
A recent preclinical study reports that scientists reversed signs of aging in liver cells and reduced levels of an Alzheimer’s-associated protein by roughly 50%, pointing to a potential peripheral strategy to influence neurodegeneration. The result is promising but early — safety, replication, and human translation remain major hurdles.

Blood Test Detects Alzheimer’s Risk a Decade Before Symptoms
Emerging blood tests that measure proteins such as phosphorylated tau and amyloid ratios can identify people at elevated risk of Alzheimer’s disease long before memory loss appears, opening possibilities for earlier intervention, better trial design, and difficult ethical choices.